Roche moves deep­er in­to Mer­ck ter­ri­to­ry with Tecen­triq/chemo OK in front­line NSCLC

Roche has nailed down the FDA ap­proval it needs to catch up with Mer­ck in front­line non-squa­mous non-small cell lung can­cer, po­si­tion­ing Tecen­triq for a broad­er swath of pa­tients.

The lat­est OK cov­ers the use of the PD-L1 drug in com­bi­na­tion with a chemother­a­py reg­i­men com­pris­ing Abrax­ane and car­bo­platin in NSCLC pa­tients whose can­cer has metas­ta­sized and doesn’t car­ry EGFR or ALK ge­nom­ic tu­mor aber­ra­tions.

It’s a sim­i­lar la­bel to Mer­ck’s PD-1 star Keytru­da, which was ap­proved in con­junc­tion with a dif­fer­ent type of chemo for front­line treat­ment last Au­gust.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER